PHASERX, INC.

Profile

Company Names

PHASERX, INC.
PHASERX INC

Addresses

410 WEST HARRISON STREET, SUITE 300, SEATTLE, WA 98119

454 NORTH 34TH STREET, SEATTLE, WA 98103

Phone Numbers

206-805-6300
206-812-1530

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2006

State Incorporated:

DELAWARE

Total Amount Raised:

$13,816,671.00

Number of Funding Rounds:

9
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
9
2016-06-07 
$0.00 
$420,000.00 
$420,000.00 
 
8
2015-12-21 
$4,000,000.00 
$4,000,000.00 
$0.00 
Debt 
7
2013-12-04 
$0.00 
$1,540,015.00 
$1,540,015.00 
Debt 
6
2013-09-19 
$1,400,014.00 
$1,400,014.00 
$0.00 
Debt 
5
2013-06-28 
$500,005.00 
$1,400,014.00 
$900,009.00 
Debt 
4
2012-12-10 
$1,500,016.00 
$3,000,031.00 
$1,500,015.00 
Debt 
3
2012-07-02 
$1,600,016.00 
$1,600,016.00 
$0.00 
Debt 
2
2012-02-01 
$3,600,037.00 
$4,650,037.00 
$1,050,000.00 
Debt 
1
2009-08-17 
$1,216,583.00 
$1,216,583.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
BRIAN 
 
ATWOOD 
DIRECTOR
IMMUNE DESIGN CORP.   |  VERACYTE, INC.   |  MIRINA CORP   |  FIVE PRIME THERAPEUTICS INC   |  GROOVE BIOPHARMA CORP   |  PHASERX, INC.   |  ATRECA, INC.   |  CELL DESIGN LABS, INC.   |  CERO THERAPEUTICS HOLDINGS, INC.
BRIAN 
G. 
ATWOOD 
DIRECTOR
HELICOS BIOSCIENCES CORP   |  PHASERX INC   |  OPGEN INC   |  TRIUS THERAPEUTICS INC   |  VERSANT AFFILIATES FUND I-B LP   |  VERSANT AFFILIATES FUND I-A LP   |  VERSANT SIDE FUND I LP   |  VERSANT SIDE FUND II, LP   |  PHASERX, INC.   |  CLOVIS ONCOLOGY, INC.   |  VERACYTE, INC.   |  CERO THERAPEUTICS HOLDINGS, INC.
RAYMOND 
 
CALVERT 
EXECUTIVE OFFICER
PHASERX INC
JOHN 
 
DIEKMAN 
DIRECTOR
IGENICA INC   |  5AM CO-INVESTORS III, L.P.   |  PHENOMIX CORP   |  PHASERX, INC.   |  5AM CO-INVESTORS IV, L.P.   |  IGENICA BIOTHERAPEUTICS, INC   |  IDEAYA BIOSCIENCES, INC.
JOHN 
D. 
DIEKMAN 
DIRECTOR
AMBRX INC   |  PHASERX INC   |  INGENUITY SYSTEMS INC   |  PHASERX, INC.   |  IDEAYA BIOSCIENCES, INC.
STEVEN 
 
GILLIS 
DIRECTOR
TRUBION PHARMACEUTICALS, INC   |  PHASERX INC   |  PULMATRIX INC   |  THERACLONE SCIENCES, INC.   |  MIRINA CORP   |  SURFACE LOGIX INC   |  ACYLIN THERAPEUTICS, INC.   |  BLUEBIRD BIO, INC.   |  VARIATION BIOTECHNOLOGIES (US), INC.   |  GROOVE BIOPHARMA CORP   |  ALLOZYNE INC   |  PHASERX, INC.   |  VIRAL LOGIC SYSTEMS TECHNOLOGY CORP   |  FARADAY PHARMACEUTICALS, INC.   |  PULMATRIX OPERATING COMPANY, INC.   |  LYCERA CORP   |  PULMATRIX, INC.   |  NEXGENIA INC.   |  CODIAK BIOSCIENCES, INC.   |  VBI VACCINES INC/BC   |  NOHLA THERAPEUTICS INC.   |  HOMOLOGY MEDICINES, INC.   |  IMMUSANT, INC.   |  ONCORESPONSE INC   |  EGENESIS, INC.   |  ARCH VENTURE FUND X, L.P.   |  ARCH VENTURE FUND X OVERAGE, L.P.   |  ARCH VENTURE FUND XI, L.P.   |  HC BIOSCIENCE, INC.   |  ARCH VENTURE FUND XII, L.P.   |  PHEAST THERAPEUTICS, INC.   |  SONOTHERA, INC.   |  PRONIRAS CORP   |  ONCORESPONSE, INC
MICHELLE 
 
GRIFFIN 
DIRECTOR
PHASERX, INC.   |  ACER THERAPEUTICS INC.
MICHAEL 
 
HOUSTON 
EXECUTIVE OFFICER
PHASERX, INC.   |  OPTICSURG INC.   |  ELEVATEU, INC.
PAUL 
 
JOHNSON 
EXECUTIVE OFFICER, DIRECTOR
PHASERX, INC.   |  CHEYENNE SURGICAL CENTER LLC   |  HIGH PLAINS PHYSICIANS, LLC   |  LOTLINX, INC.   |  TM DELIVERY SYSTEMS, LLC   |  ICEBREAKER HEALTH, INC.   |  NEXT FRONTIER BIOSCIENCES, LLC   |  LUMANU, INC.   |  REDIRECT HEALTH, LLC   |  NEXT FRONTIER BIOSCIENCES, INC.   |  SISC DOCTOR COMPANY, LLC   |  SUNRISE BANCSHARES, INC.   |  CHOICEONE FINANCIAL SERVICES INC   |  WORKING ALONG YOUR SIDE WAYS INC   |  KINETIC PRESSURE CONTROL LTD   |  SP MAGNOLIA 2 LLC   |  FORECASTABLE, INC.   |  TEMPERO BIO, INC.   |  ZIA CREDIT UNION
PAUL 
H. 
JOHNSON 
EXECUTIVE OFFICER, DIRECTOR
PHASERX INC   |  PHASERX, INC.
ANDREW 
 
LEON 
EXECUTIVE OFFICER
PHASERX INC   |  PHASERX, INC.
ROBERT 
W. 
OVERELL 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
PHASERX INC   |  PHASERX, INC.
JOHN 
 
SCHMIDT 
DIRECTOR
CP EQUITY LLC   |  GOPICNIC BRANDS, INC.   |  PHASERX, INC.   |  AIRESOURCE TECHNOLOGIES, LLC   |  KEW MEDIA GROUP INC.
JOHN 
A. 
SCHMIDT 
DIRECTOR
PHASERX, INC.
SHING-YIN (HELEN) 
 
TSUI 
EXECUTIVE OFFICER
PHASERX, INC.
RICHARD 
 
ULEVITCH 
DIRECTOR
PHASERX, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2016-06-09
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2016-06-07 
2015-12-29
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2015-12-21 
2013-12-17
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2013-12-04 
2013-10-02
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2013-09-19 
2013-07-11
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2013-06-28 
2012-12-21
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2012-12-10 
2012-07-06
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2012-07-02 
2012-02-14
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2012-02-01 
2010-02-22
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2009-08-17 
2009-08-26
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2009-08-17 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
PALLADIUM CAPITAL ADVISORS, LLC
129400